The role of CD147 in ischemic inflammation and brain injury

CD147在缺血性炎症和脑损伤中的作用

基本信息

批准号：
8877660
负责人：
Guohong Li
金额：
$ 31.72万
依托单位：
LOUISIANA STATE UNIV HSC SHREVEPORT
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-01 至 2016-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8877660
关键词：
Acute Acute myocardial infarction Adoptive Transfer Alzheimer&apos s Disease Animal Model Anti-Inflammatory Agents Anti-inflammatory Antibodies Atrophic Blocking Antibodies Blood Circulation Blood Vessels Brain Brain Injuries CD147 antigen Cardiovascular Diseases Cause of Death Cells Cerebral Ischemia Cyclophilin A Cyclophilins Data Development Excision Experimental Autoimmune Encephalomyelitis Functional disorder Health ITGAM gene Immune Immune System Diseases Immune response Immunoglobulin G Infection Infiltration Inflammation Inflammation Mediators Inflammatory Inflammatory Response Injury Investigation Ischemic Stroke Leukocytes Lung Matrix Metalloproteinases Mediating Mediator of activation protein Membrane Glycoproteins Middle Cerebral Artery Occlusion Modeling Molecular Multiple Sclerosis Mus Myocardial Pathogenesis Pathology Patients Peripheral Play Pneumonia Rattus Receptor Signaling Recovery of Function Reporting Risk Role Secondary to Severity of illness Small Interfering RNA Source Spleen Stroke Study Section T-Lymphocyte Techniques Testing Therapeutic Time base cell type clinically relevant cytokine disability extracellular human disease insight intravenous injection leukocyte activation macrophage migration monocyte nervous system disorder novel post stroke protein expression response therapeutic target

项目摘要

DESCRIPTION (provided by applicant): This R01 application aims to investigate novel roles of CD147 in stroke-induced peripheral immune dysfunction and stroke pathology. Recent studies, including our own, favor an important notion that stroke-induced peripheral immune dysfunction not only predisposes patients to post-stroke infections (particularly pneumonia) but also contributes to secondary brain damage by exacerbating and perpetuating inflammatory response in the post-ischemic brain. The spleen has emerged as a novel target that mediates the peripheral immune response after stroke. Based on the novel findings discussed in the Preliminary Studies section, we propose the central hypothesis that CD147 acts as a novel key regulator of the splenic response to focal cerebral ischemia and that contributes importantly to secondary brain damage after stroke. Specifically, we propose that spleen monocytes play a critical role in stroke- mediated brain injury through a novel CD147 mechanism. Specific Aim 1 will test the hypothesis that CD147 contributes importantly to ischemic inflammation and brain injury and thus therapeutic blockade of CD147 provides neurovascular protection in ischemic stroke. Aim 1a: We will investigate whether therapeutic targeting of CD147 provides neurovascular protection in ischemic stroke. Anti-CD147 function-blocking antibodies will be given by intravenous injection at clinically relevant time points. Aim 1b: We will investigate the cellular and molecular mechanisms by which CD147 contributes to stroke injury, with a focus on examining brain leukocyte infiltration, BBB disruption, and the splenic inflammatory activation after stroke. Aim 1c: We will determine whether therapeutic targeting of CD147 has long-term beneficial effects on functional recovery after stroke. Specific Aim 2 will test the hypothesis tha CD147 is a key mediator of the spleen's immune response and contribution to ischemic stroke through spleen inflammatory monocytes. Aim 2a: We will determine the cell-type specific expression of CD147 in the spleens of mice subjected to tMCAO and the role of CD147 in inflammatory activation of splenic immunocytes (particularly monocytes, T cells) after stroke. Aim 2b: By adoptive transfer of spleen monocytes into splenectomized mice, we will determine whether spleen inflammatory monocytes contribute importantly to stroke injury. To selectively target CD147 on spleen monocytes, siRNA knockdown technique will be used. Aim 2c: We will determine the effects of therapeutic targeting of CD147 on stroke-induced splenic atrophy and poststroke infections. These studies will reveal novel roles of CD147 in the spleen's immune response and contribution to cerebral ischemia, and the findings may have potential implications for developing novel treatments for stroke.

描述（由申请人提供）：该 R01 申请旨在研究 CD147 在中风引起的外周免疫功能障碍和中风病理学中的新作用。最近的研究，包括我们自己的研究，都支持一个重要的观点，即中风引起的外周免疫功能障碍不仅使患者容易发生中风后感染（特别是肺炎），而且还通过加剧和维持缺血后大脑中的炎症反应而导致继发性脑损伤。。脾脏已成为介导中风后外周免疫反应的新靶点。基于初步研究部分讨论的新发现，我们提出了一个中心假设：CD147 是脾脏对局灶性脑缺血反应的新型关键调节因子，对中风后继发性脑损伤有重要影响。具体来说，我们提出脾单核细胞通过一种新的 CD147 机制在中风介导的脑损伤中发挥关键作用。具体目标 1 将检验以下假设：CD147 对缺血性炎症和脑损伤有重要影响，因此治疗性阻断 CD147 可在缺血性中风中提供神经血管保护。目标 1a：我们将研究 CD147 的治疗靶向是否可以为缺血性中风提供神经血管保护。抗 CD147 功能阻断抗体将在临床相关时间点通过静脉注射给予。目标 1b：我们将研究 CD147 导致中风损伤的细胞和分子机制，重点是检查中风后脑白细胞浸润、血脑屏障破坏和脾脏炎症激活。目标 1c：我们将确定 CD147 的治疗靶向是否对中风后功能恢复具有长期有益影响。具体目标 2 将检验以下假设：CD147 是脾脏免疫反应的关键介质，并通过脾脏炎症单核细胞导致缺血性中风。目标 2a：我们将确定接受 tMCAO 的小鼠脾脏中 CD147 的细胞类型特异性表达以及 CD147 在中风后脾脏免疫细胞（特别是单核细胞、T 细胞）炎症激活中的作用。目标 2b：通过将脾单核细胞过继转移至脾切除小鼠体内，我们将确定脾脏炎症单核细胞是否对中风损伤有重要影响。为了选择性地靶向脾单核细胞上的 CD147，将使用 siRNA 敲低技术。目标 2c：我们将确定 CD147 治疗靶向对中风引起的脾萎缩和中风后感染的影响。这些研究将揭示 CD147 在脾脏免疫反应和脑缺血中的新作用，这些发现可能对开发新的中风治疗方法具有潜在意义。